156 related articles for article (PubMed ID: 9333065)
1. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa.
Nakano M; Deguchi T; Kawamura T; Yasuda M; Kimura M; Okano Y; Kawada Y
Antimicrob Agents Chemother; 1997 Oct; 41(10):2289-91. PubMed ID: 9333065
[TBL] [Abstract][Full Text] [Related]
2. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
[TBL] [Abstract][Full Text] [Related]
3. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Tankovic J; Perichon B; Duval J; Courvalin P
Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
[TBL] [Abstract][Full Text] [Related]
4. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
5. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Akasaka T; Tanaka M; Yamaguchi A; Sato K
Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
[TBL] [Abstract][Full Text] [Related]
6. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
Mouneimné H; Robert J; Jarlier V; Cambau E
Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
[TBL] [Abstract][Full Text] [Related]
7. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
8. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
9. In vivo selection of Pseudomonas Aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection.
Nakano M; Yasuda M; Yokoi S; Takahashi Y; Ishihara S; Deguchi T
Urology; 2001 Jul; 58(1):125-8. PubMed ID: 11445503
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii.
Nishino Y; Deguchi T; Yasuda M; Kawamura T; Nakano M; Kanematsu E; Ozeki S; Kawada Y
FEMS Microbiol Lett; 1997 Sep; 154(2):409-14. PubMed ID: 9311142
[TBL] [Abstract][Full Text] [Related]
11. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance and novel mutations detected in the gyrA and parC genes of Pseudomonas aeruginosa strains isolated from companion dogs.
Park Y; Oh J; Park S; Sum S; Song W; Chae J; Park H
BMC Vet Res; 2020 Apr; 16(1):111. PubMed ID: 32293442
[TBL] [Abstract][Full Text] [Related]
13. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa.
Higgins PG; Fluit AC; Milatovic D; Verhoef J; Schmitz FJ
Int J Antimicrob Agents; 2003 May; 21(5):409-13. PubMed ID: 12727072
[TBL] [Abstract][Full Text] [Related]
14. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.
Kureishi A; Diver JM; Beckthold B; Schollaardt T; Bryan LE
Antimicrob Agents Chemother; 1994 Sep; 38(9):1944-52. PubMed ID: 7811002
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
Jalal S; Wretlind B
Microb Drug Resist; 1998; 4(4):257-61. PubMed ID: 9988043
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography.
Matsumoto M; Shigemura K; Shirakawa T; Nakano Y; Miyake H; Tanaka K; Kinoshita S; Arakawa S; Kawabata M; Fujisawa M
Int J Antimicrob Agents; 2012 Nov; 40(5):440-4. PubMed ID: 22884856
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
18. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.
Okuda J; Hayakawa E; Nishibuchi M; Nishino T
Antimicrob Agents Chemother; 1999 May; 43(5):1156-62. PubMed ID: 10223929
[TBL] [Abstract][Full Text] [Related]
19. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones.
Takenouchi T; Sakagawa E; Sugawara M
Antimicrob Agents Chemother; 1999 Feb; 43(2):406-9. PubMed ID: 9925546
[TBL] [Abstract][Full Text] [Related]
20. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
